Copyright © 2004 by the European Society of Cardiology.
Clinical research
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism
Periprocedural safety and mid-term follow-up results of three different device occluder systems
a Internal Medicine II, Department of Cardiology, Technical University of Dresden, Fetscherstr. 76, 01307 Dresden, Germany
b Internal Medicine, Department of Cardiology, Charité University of Berlin, Germany
c Department of Neurology, University of Technology Dresden, Germany
d Internal Medicine, Theresienkrankenhaus Mannheim, Germany
e Bethanien Hospital – CCB, Frankfurt/Main, Germany
* Corresponding author. Tel.: +49-351-450-1700/1701; fax: +49-351-450-1702
E-mail address: Martin.Braun{at}mailbox.tu-dresden.de
Received 30 January 2003; revised 15 September 2003; accepted 16 October 2003 See page 361 for the editorial comment on this paper1
Abstract
Aims Interventional PFO closure has previously been reported to reduce the risk for recurrent thromboembolic events. The aim of the present study was to evaluate three different occluder systems in respect to (a) the safety and practicability and (b) the mid-term risk of recurrent thromboembolic events.
Methods and results Since 08/98 until 12/02, 307 consecutive patients (138 women, 169 men, mean age 43 years) with a symptomatic PFO underwent PFO closure using the PFO-Star (
), AmplatzerTM PFO occluder (
) and CardioSeal/Starflex (
). Implantation was successful in all patients. Periinterventional complications occurred in 9 patients (5x ST-segment elevations, 1x arteriovenous fistula, 2x TIA, 1x device dislodgement). All of them were reversible and not associated with a specific type of device. During the median follow-up of 24 months (25/75th percentiles: 14/37 months), the annual risk of recurrence was 0.6% for TIA, 0% for stroke and 0.2% for peripheral embolism (PFO-Star: 0.8%, AmplatzerTM PFO occluder: 0.7% and CardioSeal/Starflex: 1.0%).
Conclusion Interventional PFO closure appears to be safe and a promising technique in symptomatic PFO patients with a low incidence of periinterventional complications and recurrent thromboembolic events using three different devices (PFO-Star, AmplatzerTM PFO occluder or the CardioSeal/Starflex).
Key Words: Embolism • Heart septal defects • Cerebral ischemia • Transcatheter closure
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Patent foramen ovale: the jury is still out
- Horst Sievert and Margaret Taaffe
EHJ 2004 25: 361-362.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  W Budts, E Troost, and J-U Voigt Optimising device imaging in atrial septal closure by three-dimensional transoesophageal echocardiography Heart, September 1, 2008; 94(9): 1110 - 1110. [Full Text] [PDF]
|
|
|
|
|
|
A Wahl, M Kunz, A Moschovitis, T Nageh, M Schwerzmann, C Seiler, H P Mattle, S Windecker, and B Meier Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism Heart, March 1, 2008; 94(3): 336 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Kenny, M Turner, and R Martin When to close a patent foramen ovale Arch. Dis. Child., March 1, 2008; 93(3): 255 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bedard, J. Rodes-Cabau, C. Houde, A. Mackey, D. Rivest, S. Cloutier, M. Noel, A. Marrero, J.-M. Cote, P. Chetaille, et al. Enhanced Thrombogenesis but Not Platelet Activation Is Associated With Transcatheter Closure of Patent Foramen Ovale in Patients With Cryptogenic Stroke Stroke, January 1, 2007; 38(1): 100 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Khatri and S. E. Kasner Ischemic strokes after cardiac catheterization: opportune thrombolysis candidates? Arch Neurol, June 1, 2006; 63(6): 817 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Spies, R. Strasheim, I. Timmermanns, and R. Schraeder Patent foramen ovale closure in patients with cryptogenic thrombo-embolic events using the Cardia PFO occluder Eur. Heart J., February 1, 2006; 27(3): 365 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schwerzmann and O. Salehian Hazards of percutaneous PFO closure Eur J Echocardiogr, December 1, 2005; 6(6): 393 - 395. [Full Text] [PDF]
|
|
|
|
|
|
T. Christen, F. Mach, D. Didier, A. Kalangos, V. Verin, and P. T. Trindade Late cardiac tamponade after percutaneous closure of a patent foramen ovale Eur J Echocardiogr, December 1, 2005; 6(6): 465 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Homma and R. L. Sacco Patent Foramen Ovale and Stroke Circulation, August 16, 2005; 112(7): 1063 - 1072. [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. Mahle, K. Lundine, K. R. Kanter, J. M. Forbess, P. Kirshbom, S. R. Tosone, and R. N. Vincent The short term effects of cardiopulmonary bypass on neurologic function in children and young adults Eur. J. Cardiothorac. Surg., November 1, 2004; 26(5): 920 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Krumsdorf, S. Ostermayer, K. Billinger, T. Trepels, E. Zadan, K. Horvath, and H. Sievert Reply J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1714 - 1716. [Full Text] [PDF]
|
|
|
|
|
|
H. Sievert and M. Taaffe Patent foramen ovale: the jury is still out Eur. Heart J., March 1, 2004; 25(5): 361 - 362. [Full Text] [PDF]
|
|